PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Paroxetin (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
12/08/2015
Donepezil
PRAC signal recommendation
|
10/08/2015
Risiko für Rhabdomyolyse.
Nähere Informationen finden Sie auf der Website der EMA.
Dexlansoprazol, Esomeprazol, Lansoprazol, Omeprazol, Pantoprazol, Rabeprazol
PRAC signal recommendation
|
10/08/2015
Nähere Informationen finden Sie auf der Website der EMA.
Budesonid (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Captopril/Hydrochlorothiazid (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Ciprofloxacin (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Clarithromycin (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Epirubicin (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Fluconazol (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015
Tiaprid (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
10/08/2015